Sign Out
GIOTRIF as monotherapy is indicated for the treatment of locally advanced or metastatic non-squamous non-small cell lung carcinoma with adenocarcinoma is predominantly, Epidermal Growth Factor Receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, TKI-naive adult patients.
Limitation of Use: Safety and efficacy of GIOTRIF have not been established in patients whose tumors have other EGFR mutations.
